Home > Result Summaries: Compounds > Hepatitis A Vaccine, Inactivated Result Summaries: Hepatitis A Vaccine, Inactivated GSKStudy ID Phase Title Summary (Download) 100571 (M138) phase 3 Long-term follow-up study to evaluate the immune persistence of GSK Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per ml and injected according to a 0, 12-month schedule in healthy adult volunteers (2 citation(s)) 100576 (Y11) phase 3 Long term follow-up study to evaluate the immune persistence of GSK Biologicals' inactivated hepatitis A vaccine containing 1440 EL.U of antigen per ml and injected according to a 0, 6-month schedule in healthy adult subjects (10 citation(s)) 104147 Phase 4 A multicentric, post-marketing surveillance to monitor the safety and reactogenicity of GlaxoSmithKline Biologicals Hepatitis A vaccine administered in Korean population. (1 citation(s)) 104902 Phase 3 Primary and long-term follow-up study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy female subjects aged 10-14 years. (6 citation(s)) 104951 phase 3 Evaluate the immunogenicity & safety of GSK Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a 0,1,6 mth schedule in healthy female subjects aged 10–14 yrs (2 citation(s)) 106208 phase 2 To assess reactogenicity and immunogenicity of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine, when co-administered with GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix™ hexa) at 2, 4 and 6 months of age. (4 citation(s)) 109563_1 phase 3 COMPAS: A phase III study to demonstrate efficacy of GSK Biologicals' 10-valent pneumococcal vaccine (GSK1024850A) against Community Acquired Pneumonia and Acute Otitis Media (8 citation(s)) 110031_ phase 2 Phase II, observer-blind follow-up study to assess reacto-and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine (GSK1024850A), when given as booster in primed children or as 2-dose catch-up in unprimed children. (2 citation(s)) 110058_1 phase 2 Immunogenicity of GlaxoSmithKline Biologicals' MMRV vaccine (208136) vs. ProQuad®, when coadministered with hepatitis A and pneumococcal conjugate vaccines to children 12-14 months of age. (1 citation(s)) 111442_1 phase 3 Evaluation of effectiveness of GSK Biologicals’ pneumococcal conjugate vaccine 1024850A against invasive disease (4 citation(s)) 111870_ phase 2 Immunogenicity of GlaxoSmithKline Biologicals’ MMR vaccine (209762) vs. M-M-R® II, when co-administered with hepatitis A, varicella and pneumococcal conjugate vaccines to children 12-15 months of age (1 citation(s)) 112158 n\a Epidemiologic surveillance to assess trends in acute hepatitis A among children in Panama (0 citation(s)) 112263 n\a Time trend analysis of the incidence of hepatitis- related outcomes (viral hepatitis A and unspecified viral hepatitis) reported to the Surveillance System of Panama, 2000-2010 (0 citation(s)) 112595_1 phase 3 Impact on nasopharyngeal carriage, acute otitis media, immunogenicity and safety of GSK Biologicals’ pneumococcal conjugate vaccine 1024850A (3 citation(s)) 113564 n\a Sero-prevalence of Hepatitis A Varicella-Zoster virus, Cytomegalovirus, Herpes Simplex and Bordetella pertussis in Mexico (3 citation(s)) 114451__ phase 4 Immunogenicity and safety study of GSK Biologicals’ seasonal (2010-2011) influenza vaccine FluarixTM in children previously vaccinated with GSK Biologicals’ H1N1 vaccine PandemrixTM (1 citation(s)) 114452_2 phase 4 Immunogenicity and Safety Study of GSK Biologicals' Seasonal (2010-2011) Influenza Vaccine FluarixTM in Adolescents Previously Vaccinated With GSK Biologicals' H1N1 Vaccine PandemrixTM (1 citation(s)) 114541_1 phase 3 Efficacy study of GSK Biologicals’ quadrivalent influenza vaccine, GSK2282512A, (FLU Q-QIV) when administered in children (1 citation(s)) 208109/085 Phase 3 A randomized, controlled, double-blind field efficacy trial of SmithKline Beecham Biologicals' inactivated hepatitis A vaccine using a recombinant DNA hepatitis B vaccine, Engerix®-B as control. (1 citation(s)) 208109/127 Phase 3 Open study of the immunogenicity and reactogenicity of SmithKline Beecham Biologicals' inactivated hepatitis A vaccine administered to hemophiliac patients. (1 citation(s)) 208109/139 Phase 4 Evaluation of the safety and immunogenicity of a Hepatitis A Vaccine in Patients with Chronic Viral Hepatitis B and C and chronic liver disease of other etiology. (1 citation(s)) 208109/141 Phase 4 A pilot open group study to compare the immunogenicity, reactogenicity and safety of a standard course of hepatitis A vaccine in: HIV positive individuals with haemophilia, HIV negative individuals with haemophilia, HIV negative healthy adult male controls. (0 citation(s)) 208109/145 Phase 3 A study to assess the immunogenicity and reactogenicity of hepatitis A vaccine administered subcutaneously to patients with congenital coagulation disorders using a single primary dose and a booster at six months at a dose of 1440 ELU (in 1 ml) to adults and 720 ELU (in 0.5 ml) to children. (1 citation(s)) 208109/166 Phase 4 A double-blind, randomized, placebo controlled study to evaluate the safety and immunogenicity of Havrix( in subjects with human immunodeficiency virus (HIV) infection (1 citation(s)) 208109/188 Phase 3 Study in healthy 2-month old infants to evaluate immunogenicity and reactogenicity of SmithKline Beecham Biologicals’ inactivated hepatitis A vaccine injected at the age of 2, 4 and 6 months (1 citation(s)) 208109/206 Phase 4 An open multicentric post-marketing surveillance study of the inactivated hepatitis A vaccine (Havrix™), injected according to the prescribing information enclosed, in healthy children and adults. (0 citation(s)) 208109/208 Phase 4 Drug use surveillance of Havrix® (Hepatitis A vaccine) in Korea (0 citation(s)) 208109/210 Phase 4 A Phase 4, open, comparative, multicenter study of the immunogenicity and safety of SB Bios' inactivated hepatitis A vaccine 720 EL.U/ 0.5 ml on a 0-6-month schedule, admin by intramuscular injection, either to children aged 15-18 mths old or 11-13 mths old, when compared to 23-25 mth-old children (1 citation(s)) 208109/220 phase 3 A Phase IIIb, open, randomized, controlled, multicenter study of the immunogenicity and safety of GSK Biologicals' inactivated hepatitis A vaccine administered on a 0-6 mth schedule concomitantly with Wyeth Lederle's pneumococcal conjugate vaccine in healthy children 15 months of age (1 citation(s)) 208109/228 Phase 4 A phase IV open study to assess the anamnestic response to a single intramuscular injection of GSK Bios’ hepatitis A vac, Havrix™ Junior in healthy adult subjects who have had a previously documented seropositive status following a full course of primary vaccination with GSK Bios’ hepatitis A vac (2 citation(s)) 208109/229 Phase 3 A Phase IIIb, open, multicenter study of the immunogenicity and safety of one dose of GSK Bios' inactivated hepatitis A vaccine administered to healthy children who were seropositive for anti-HAV (0 citation(s)) 208109/231 phase 3 Immunogenicity & Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine (VARIVAX™) to Children 15 m of Age (1 citation(s)) 208109/232 phase 3 Immunogenicity and Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) co-administered With GSK Biologicals' DTaP Vaccine (Infanrix™) and Aventis Pasteur's Haemophilus b Conjugate Vaccine (ActHIB) in Healthy Children 15 months of Age (1 citation(s)) 208141/039_ phase 3 A double-blind, randomized, controlled Phase III study to assess the prophylactic efficacy and safety of gD-Alum/MPL vaccine in the prevention of genital herpes disease in young women who are HSV-1 and -2 seronegative. (1 citation(s)) 208141/040 phase 3 A study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' herpes simplex candidate vaccine (gD2‑AS04) in healthy HSV seronegative and seropositive female subjects aged 10-17 years. (2 citation(s)) 217744/066 Phase 3 Open, randomized, multicentre, phase III clinical trial to assess the reactogenicity and immunogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals’ DTPa-HBV-IPV/Hib vaccine, co-administered during the same visit with GSK Biologicals’ HAV vaccine (Havrix(), in children in their second ... (0 citation(s)) 270362/002 Phase 3 A phase III open study designed to evaluate the immunogenicity and reactogenicity of a booster dose of Havrix 1440TM in healthy volunteers previously vaccinated with a single dose of SB Biologicals’ combined Vi polysaccharide typhoid and inactivated hepatitis A vaccine. (0 citation(s)) 270362/004 Phase 3 A single-blind, randomized study to evaluate the immunogenicity and reactogenicity of two production lots of GSK Bios’ combined Vi polysaccharide typhoid and inactivated hepatitis A vaccine stored between 2 °C-8 °C for either 0-12 or 24-36 mths and admin as a single dose to healthy adult volunteers (0 citation(s)) 270362/006 phase 3 A phase III, open, randomized, multicentric study to compare the reactogenicity and immunogenicity of GSK Bios’ combined Vi polysaccharide typhoid vac and inactivated hepatitis A vac, to that elicited by GSK Bios’ hepatitis A vac, admin singly or concomitantly with GSK Bios’ Vi polysaccharide vac (0 citation(s)) 347414/010 phase 3 Assess, in young children, the efficacy in preventing acute otitis media (AOM) of GSK Biologicals undecavalent pneumococcal-protein D conjugate vaccine, when administered as a three dose primary vaccination course during the first year of life with a booster dose in the second year of life. (7 citation(s)) 580299/008_ phase 3 Efficacy of GSK Bio HPV Vaccine (580299) vs Hepatitis A Vaccine as Control in Prevention of Persistent HPV-16/18 Cervical Infection & Cervical Neoplasia, administered intramuscularly according to 0,1,6 month Schedule in Healthy Females (15-25 years) (48 citation(s)) 580299/009_1 phase 3 A double blind, controlled, randomized, phase III study of the efficacy of an HPV16/18 VLP vaccine in the prevention of advanced cervical intraepithelial neoplasia associated with HPV16 or HPV18 cervical infection in healthy young adult women in Costa Rica (18 citation(s)) 710158/002 Phase 2 A primary vaccination study to evaluate immunogenicity, safety & reactogenicity of 3 doses of GSK Biologicals/Finlay’s meningococcal B candidate vaccine given intramuscularly using either 0-2-4 mth or 0-1-6 mth schedule to healthy subjects aged 12-18 yrs (1 citation(s))
